Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

67.37USD
22 May 2015
Change (% chg)

$-0.17 (-0.25%)
Prev Close
$67.54
Open
$67.50
Day's High
$68.07
Day's Low
$67.31
Volume
619,250
Avg. Vol
769,171
52-wk High
$77.30
52-wk Low
$65.95

BAX.N

Chart for BAX.N

About

Baxter International Inc. (Baxter) is a global, diversified healthcare company. The Company through its subsidiaries, develops, manufactures and markets products that sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $36,666.41
Shares Outstanding(Mil.): 544.25
Dividend: 0.52
Yield (%): 3.09

Financials

  BAX.N Industry Sector
P/E (TTM): 19.83 38.87 39.17
EPS (TTM): 3.40 -- --
ROI: 9.69 11.34 15.58
ROE: 23.34 13.34 16.57
Search Stocks

Novo Nordisk, Baxter clash over haemophilia drug patent

- Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

20 May 2015

Novo Nordisk, Baxter clash over hemophilia drug patent

COPENHAGEN - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

20 May 2015

UPDATE 1-Novo Nordisk, Baxter clash over haemophilia drug patent

COPENHAGEN, May 20 - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

20 May 2015

Novo Nordisk rejects Baxter patent claim over Novoeight

COPENHAGEN, May 20 - Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia, the Danish company said on Wednesday.

20 May 2015

REUTERS BUSINESS NEWS SCHEDULE 1830 GMT/2:30 PM ET

Verizon Communications Inc says it will buy AOL Inc in a $4.4 billion deal that gives the biggest U.S. wireless carrier access to AOL's successful digital advertising service and content including the Huffington Post news website. (AOL-M&A/VERIZON COMMN (UPDATE 6), moving shortly, by Jennifer Saba, Devika Krishna Kumar and Abhirup Roy, 588 words)

12 May 2015

Baxter buys cancer drugs from Italian drugmaker for $900 million

- Baxter International Inc said it agreed to buy two drugs to treat a rare form of blood cancer from Italian drugmaker Sigma-Tau Finanziaria SpA for $900 million, before expenses.

12 May 2015

UPDATE 1-Baxter buys cancer drugs from Italian drugmaker for $900 mln

May 12 - Baxter International Inc said it agreed to buy two drugs to treat a rare form of blood cancer from Italian drugmaker Sigma-Tau Finanziaria SpA for $900 million, before expenses.

12 May 2015

Baxter buys cancer drugs from Italian drugmaker for $900 mln

May 12 - Baxter International Inc said it agreed to buy Italian drugmaker Sigma-Tau Finanziaria SpA's portfolio of drugs to treat rare forms of blood cancer for $900 million, before expenses.

12 May 2015

Fitch Maintains Baxter International on Rating Watch Negative

(The following statement was released by the rating agency) CHICAGO, March 20 (Fitch) Fitch Ratings has maintained Baxter International Inc.'s (Baxter; NYSE: BAX) long- and short-term ratings on Rating Watch Negative. Fitch placed the company's ratings on Negative Watch in March 2014 when Baxter announced it plans to spin off its BioScience business. A full list of the company's ratings follows at the end of this press release. The ratings apply to approximately $9.21 billion of debt outsta

20 Mar 2015

BRIEF-Co don AG reaches milestone for EU-wide approval

* Reaches milestone for EU-wide approval: successful patient recruitment for phase III clinical trial Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Jan 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$1,000.00
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks